Follow The Filings

TRAX First Tracks Biotherapeutics

Health Care, filed as FIRST TRACKS BIOTHERAPEUTICS (ORD SHS), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2

  • 2 Owners
  • Max 1.7%
  • $13M
  • 2 new

In 2026 Q2 Palo Alto Investors and James Silverman opened positions in First Tracks Biotherapeutics.

Who owns this now

Largest portfolio weights among holders, up to 1.7% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors New 1.7%
  2. James Silverman New 0.12%

Who owns TRAX

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 1.7% New 1.7% 603,489 $12M History
James Silverman, Opaleye Management 0.12% New 0.12% 65,000 $1.3M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TRAX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TRAX insider trades
  • None no insider bought on the open market
  • $66.8M sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. J. Anthony Ware Director
    Sale
    $1.8M 39,265 shares at $44.78 72% of stake
    Traded Sep 2 Filed Sep 4
  2. EcoR1 Capital, LLC 10% owner
    Sale
    $65M 4,705,575 shares at $13.81 60% of stake
    Traded Apr 20 Filed Apr 22

Also filed in the last 12 months, not counted as buying or selling: 8 option exercises and 1 other transaction.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 1.01,9.01
8-K 1.01,3.02,7.01,9.01
8-K 7.01,8.01,9.01
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G —
424B3
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
SCHEDULE 13G —
8-K 1.01
424B3
8-K 2.02,9.01
10-Q
424B3

Financials

US-GAAP annual figures, as tagged in Form 10-K

Newly public, no 10-K financials yet. See the 424B3.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Period archive